| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 81, 2550-2553, Copyright © 1996 by Endocrine Society
ARTICLES |
CY Jeng, WH Sheu, MM Fuh, SM Shieh, YD Chen and GM Reaven
Department of Medicine, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Gemfibrozil or placebo was administered for 3 months to 24 individuals with endogenous hypertriglyceridemia and normal glucose tolerance. Mean ( +/- SEM) fasting plasma triglyceride (TG) concentrations decreased (4.01 +/- 0.55 to 1.34 +/- 0.12 mmol/L; P < 0.001) and high density lipoprotein cholesterol concentrations increased (0.54 +/- 0.03 to 0.67 +/- 0.04 mmol/L; P < 0.001) in gemfibrozil-treated patients, associated with lower (P < 0.01-0.001) plasma free fatty acid and TG concentrations when measured at hourly intervals in response to breakfast (0800 h) and lunch (1200 h). However, day-long plasma glucose and insulin responses to meals in the 2 groups were similar before and after treatment, as were the steady state plasma glucose and insulin concentrations at the end of a 180-min infusion of somatostatin, insulin, and glucose. Thus, marked decreases in both plasma TG and free fatty acid concentrations seen in association with gemfibrozil neither enhanced insulin-mediated glucose disposal nor lowered ambient plasma insulin concentrations in patients with endogenous hypertriglyceridemia.
This article has been cited by other articles:
 |
|
 |
|
  T.-J. Wu, H.-Y. Ou, C.-W. Chou, S.-H. Hsiao, C.-Y. Lin, and P. C. Kao Decrease in Inflammatory Cardiovascular Risk Markers in Hyperlipidemic Diabetic Patients Treated with Fenofibrate Ann. Clin. Lab. Sci., January 1, 2007; 37(2): 158 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Subramanian, M. A. DeRosa, C. Bernal-Mizrachi, N. Laffely, W. T. Cade, K. E. Yarasheski, P. E. Cryer, and C. F. Semenkovich PPAR{alpha} activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1365 - E1371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Tenkanen, M. Manttari, P. T. Kovanen, H. Virkkunen, and V. Manninen Gemfibrozil in the Treatment of Dyslipidemia: An 18-Year Mortality Follow-up of the Helsinki Heart Study. Arch Intern Med, April 10, 2006; 166(7): 743 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Robins, H. B. Rubins, F. H. Faas, E. J. Schaefer, M. B. Elam, J. W. Anderson, and D. Collins Insulin Resistance and Cardiovascular Events With Low HDL Cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) Diabetes Care, May 1, 2003; 26(5): 1513 - 1517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S Elliott, N. L Keim, J. S Stern, K. Teff, and P. J Havel Fructose, weight gain, and the insulin resistance syndrome Am. J. Clinical Nutrition, November 1, 2002; 76(5): 911 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Pan, M. K. Mater, A. P. Thelen, J. M. Peters, F. J. Gonzalez, and D. B. Jump Evidence against the peroxisome proliferator-activated receptor {alpha} (PPAR{alpha}) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription J. Lipid Res., May 1, 2000; 41(5): 742 - 751. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. E. Wilson Effects of Estradiol and Exogenous Insulin-Like Growth Factor I (IGF-I) on the IGF-I Axis during Growth Hormone Inhibition and Antagonism J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4013 - 4021. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
